Acute leukemia: A pediatric perspective

Slides:



Advertisements
Similar presentations
Susanna Akiki WMRGL 2009 Acute Promyelocytic Leukemia with t(15;17) (q22;q21) developing inv(16)(p13q22) secondary AML.
Advertisements

Introduction to Leukemia
LEUKEMIA—HEMATOLOGY {S1}
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood.
Introduction to Leukemia
What is Leukemia? Leukemia is cancer of the blood. Often times, symptoms of Leukemia go unnoticed or do not appear at all in the early stages. Because.
Normal haemopoiesis. ABNORMALITIES IN THE HEMOPOIETIC SYSTEM CAN LEAD TO HEMOGLOBINOPATHIES HEMOPHILIA DEFECTS IN HEMOSTASIS/THROMBOSIS HEMATOLOGICAL.
Heterogeneous group of hematopoietic neoplasms Uncontrolled proliferation and decreased apoptotic activity with variable degrees of differentiation Composed.
MLAB 1415: Hematology Keri Brophy-Martinez
Acute Leukemia Kristine Krafts, M.D..
Nada Mohamed Ahmed, MD, MT (ASCP)i. Objectives chronic myeloid leukaemia (CML) Haematopoietic malignancies Polycythemia vera (PV) Idiopathic myelofibrosis.
The stroke size should be 0.25
Acute Leukemia Kristine Krafts, M.D..
Malignancies of hematopoietic cells. Leukemia
Volume 13, Issue 4, Pages (December 2006)
Acute Myeloid Leukemia
LEUKEMIAS H.A. MWAKYOMA, MD.
Stems Cells and the Pathways to Aging and Cancer
Molecular consequences of chromosomal rearrangements that modify the AML1/CBFβ transcription factor complex, the most frequent target of reciprocal translocations.
Age-associated changes in human hematopoietic stem cells
Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms
Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms
Illuminating the Properties of Prostate Luminal Progenitors
Dysfunctional Niches as a Root of Hematopoietic Malignancy
17 Chapter 17: Chromosome 17 Nucleus 48,473 bp 882 aa RARA Cytoplasm
Building better therapy for children with acute lymphoblastic leukemia
Volume 14, Issue 6, Pages (June 2014)
Acute Myeloid Leukemia
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Cancer Stem Cells in Hematopoietic Malignancies
Adrian G. Selim, Andrew S. Moore  The Journal of Molecular Diagnostics 
Andrew G. Muntean, Jay L. Hess  Cancer Cell 
Volume 14, Issue 4, Pages (October 2008)
Volume 13, Issue 4, Pages (December 2006)
by R. Coleman Lindsley, and Benjamin L. Ebert
The Search for Multiple Myeloma Stem Cells: The Long and Winding Road
The AML Salad Bowl Cancer Cell
Volume 13, Issue 4, Pages (December 2006)
It's ALL in the diagnosis
It's ALL in the diagnosis
Dysfunctional Niches as a Root of Hematopoietic Malignancy
Combinatorial Haplo-Deficient Tumor Suppression in 7q-Deficient Myelodysplastic Syndrome and Acute Myeloid Leukemia  Britta Will, Ulrich Steidl  Cancer.
Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions  Darius Sairafi, Mats Remberger, Michael.
An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
A New Therapeutic Target for Leukemia Comes to the Surface
Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies
Meddling with METTLs in Normal and Leukemia Stem Cells
Cutaneous Complications in Hematopoietic Cell Transplant Recipients: Impact of Biopsy on Patient Management  Oana Paun, Tycel Phillips, Pingfu Fu, Roberto.
On the Origin of Leukemic Species
Neoplastic disorder.
Iléana Antony-Debré, Ulrich Steidl  Cancer Cell 
Chronic Leukemia Dr. Noha Noufal.
Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.
Monica L. Guzman, Craig T. Jordan  Cancer Cell 
CHRONIC LEUKEMIA BY: DR. FATMA AL-QAHTANI CONSULTANT HAEMATOLOGIST
Minimal Residual Disease and Hematologic Malignancies
Hematopoietic Stem Cell Heterogeneity Takes Center Stage
Simón Méndez-Ferrer, María García-Fernández, Carlos L.F. de Castillejo 
Photomicrographs of different types of leukemia.
Hariharan Easwaran, Hsing-Chen Tsai, Stephen B. Baylin  Molecular Cell 
Attacking Cancer at Its Root
MYELOID LEUKEMIAS Dr. B.V.Vydehi M.D PROFESSOR OF PATHOLOGY
Searching for leukemia stem cells—Not yet the end of the road?
Volume 13, Issue 4, Pages (April 2008)
Cellular Alchemy and the Golden Age of Reprogramming
The AML Salad Bowl Cancer Cell
Stems Cells and the Pathways to Aging and Cancer
Presentation transcript:

Acute leukemia: A pediatric perspective James R Downing, Kevin M Shannon  Cancer Cell  Volume 2, Issue 6, Pages 437-445 (December 2002) DOI: 10.1016/S1535-6108(02)00211-8

Figure 1 Frequency of the major subtypes of hematopoietic malignancies in pediatric and adult patients The pie charts show the relative frequency of the major hematopoietic malignancies in children (0 to 19 years) and adults (>19 years). The major leukemia and lymphoma subtypes include chromic myelogenous leukemia (CML), chromic lymphocytic leukemia (CLL), Hodgkin's disease, non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), acute Lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative disease (MPD). Cancer Cell 2002 2, 437-445DOI: (10.1016/S1535-6108(02)00211-8)

Figure 2 A conceptual model of the pathogenesis of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and MDS-related AML Hematopoietic stem cells (HSC) or committee progenitors are formed early in development and persist throughout life. These cells are likely to vary in their biologic properties with age, and thus during ontogeny may also vary in their susceptibility to different oncogenic events. The acquisition of certain chromosomal translocations or rearrangements results in the production of fusion oncoproteins that typically result in the enhanced self-renewal capacity of HSC and their committed progenitors. The cells serve as a silent prelukemic population that can acquire other cooperating mutations leading to the formation of an overt leukemic clone. Two examples of this subtype of leukemia are t(8;21)-containing AML with M2 morphology (AML-M2) and t(15;17)-containing acute promyelocytic leukemia (APL). By contrast, myelodypslastic syndrome (MDS) is thought to arise through the acquisition of multiple mutations. Once established, the myelodyplastic stem cell can continue to undergo additional genetic and epigenetic changes, which in a substantial percentage of cases will lead to the development of overt AML. MDS-related AML can also occur without a preceding history of MDS. Shown are examples of the type of cellular morphology seen in a case of MDS-related AML. Cancer Cell 2002 2, 437-445DOI: (10.1016/S1535-6108(02)00211-8)